Laboratory study demonstrates concurrent biopotential and neurochemical sensing in neural models, indicating scalable capacity for multimodal brain monitoring.
The simultaneous measurement of biopotential and neurochemical signals provides a comprehensive view of the brain. Yet, most neural interfaces record solely biopotential or neurochemical activity. This work presents a complementary metal-oxide-semiconductor (CMOS) analog front-end (AFE) chip that integrates 32 biopotential amplifiers and 32 neurochemical amplifiers for parallel recording from 64 electrodes. The biopotential amplifier is a two-stage design providing a gain of 57.1 dB, a bandwidth of 0.4 Hz–6.2 kHz, and 6.7 µVRMS input-referred noise (20 kHz sampling rate). The neurochemical amplifier is a rail-to-rail folded-cascode operational amplifier with selectable transimpedance gain (91.9 kΩ to 851.9 kΩ), a dynamic range of ±15 μA to ±2 μA, respectively, a bandwidth of 12.6 kHz, and input-referred noise as low as 46.3 pARMS (20 kHz sampling rate). The neurochemical amplifiers are designed for fast-scan cyclic voltammetry (FSCV) measurements. I/O complexity is minimized using a time-division multiplexing scheme for readout, enabling straightforward scalability. The chip is fabricated using a 0.35-µm CMOS process and occupies a 3.0 × 8.3 mm2 area. In vitro recordings of catecholamines and neural spikes validate the chip’s function. The chip enables scalable, low-noise, bimodal neural recording, supporting investigations into the dynamics between neuronal biopotential activity and neurochemical signaling.
No takes yet. Share an insight, caveat, or question.
Crocker et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: